Phase 2
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Multiple Myeloma, Impaired Renal Function
Both
Multiple Myeloma, Impaired Renal Function
Trial Information
Inclusion Criteria:
- Documented diagnosis of relapsed or refractory multiple myeloma (MM).
- Age > 18 years at the time of signing the informed consent form
- Stable renal function
Exclusion Criteria:
- Documented amyloidosis
- Any prior use of Revlimid ®
- Any contraindication to Revlimid ® and especially:
- Lack of acceptable method of birth control for female of childbearing potential
(FCPB)
- Men who don't agree to use condom during the study and 4 weeks after the last
study drug intake if their partner is a FCPB.
- Pregnant or breast feeding women
Type of Study:
Interventional
Study Design:
Endpoint Classification: Pharmacokinetics Study
Authority:
France : Agence Française de sécurité sanitaire des produits de santé
Study ID:
REVIR
NCT ID:
NCT00779922
Start Date:
November 2008
Completion Date:
Related Keywords:
- Multiple Myeloma
- Impaired Renal Function
- Multiple Myeloma
- impaired renal function
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Renal Insufficiency
Name | Location |
|---|
